Pheochromocytoma and paraganglioma: Diagnosis, genetics, management, and treatment

Current Problems in Cancer

Volumn 38, Issue 1, 2014, Pages 7-41

  Martucci, Victoria L ^a   Pacak, Karel ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 2ALPHA; MEMBRANE PROTEIN; MYC ASSOCIATED FACTOR X PROTEIN; MYC PROTEIN; SUCCINATE DEHYDROGENASE; TRANSMEMBRANE PROTEIN 127; UNCLASSIFIED DRUG;

ARTICLE; BIOCHEMISTRY; CANCER CHEMOTHERAPY; DIAGNOSTIC IMAGING; EXTERNAL BEAM RADIOTHERAPY; GENE MUTATION; GENETIC ALGORITHM; GENETIC SCREENING; GENETICS; HUMAN; INCIDENCE; METASTASIS; MOLECULARLY TARGETED THERAPY; NEUROFIBROMATOSIS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; RADIOFREQUENCY ABLATION; SIPPLE SYNDROME; VON HIPPEL LINDAU DISEASE;

ADRENAL GLAND NEOPLASMS; HUMANS; PARAGANGLIOMA; PHEOCHROMOCYTOMA;

EID: 84896052975     PISSN: 01470272     EISSN: 15356345     Source Type: Journal    
DOI: 10.1016/j.currproblcancer.2014.01.001     Document Type: Article

References (246)

1. Chen H., Sippel R.S., O'Dorisio M.S., et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 2010, 39(6):775-783.
2. McNeil A.R., Blok B.H., Koelmeyer T.D., Burke M.P, Hilton J.M. Phaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland. Aust N Z J Med 2000, 30(6):648-652.
3. Anderson G.H., Blakeman N., Streeten D.H. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens 1994, 12(5):609-615.
4. Omura M., Saito J., Yamaguchi K., Kakuta Y., Nishikawa T. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 2004, 27(3):193-202.
5. Lenders J.W.M., Eisenhofer G., Mannelli M., Pacak K. Phaeochromocytoma. Lancet 2005, 366(9486):665-675.
6. Arnaldi G., Boscaro M. Adrenal incidentaloma. Best Pract Res Clin Endocrinol Metab 2012, 26(4):405-419.
7. Mannelli M., Lenders J.W., Pacak K., Parenti G., Eisenhofer G. Subclinical phaeochromocytoma. Best Pract Res Clin Endocrinol Metab 2012, 26(4):507-515.
8. Cascón A., Inglada-Pérez L., Comino-Méndez I., et al. Genetics of pheochromocytoma and paraganglioma in Spanish pediatric patients. Endocr Relat Cancer 2013, 20(3):L1-L6.
9. King K.S., Prodanov T., Kantorovich V., et al. Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. J Clin Oncol 2011, 29(31):4137-4142.
10. Waguespack S.G., Rich T., Grubbs E., et al. A current review of the etiology, diagnosis, and treatment of pediatric pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 2010, 95(5):2023-2037.
11. Burnichon N., Vescovo L., Amar L., et al. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet 2011, 20(20):3974-3985.
12. Dannenberg H., de Krijger R.R., van der Harst E., et al. Von Hippel-Lindau gene alterations in sporadic benign and malignant pheochromocytomas. Int J Cancer 2003, 105(2):190-195.
13. Gimm O., Armanios M., Dziema H., Neumann H.P., Eng C. Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma. Cancer Res 2000, 60(24):6822-6825.
14. van Nederveen F.H., Korpershoek E., Lenders J.W., de Krijger R.R., Dinjens W.N. Somatic SDHB mutation in an extraadrenal pheochromocytoma. N Engl J Med 2007, 357(3):306-308.
15. Karasek D., Shah U., Frysak Z., Stratakis C., Pacak K. An update on the genetics of pheochromocytoma. J Hum Hypertens 2013, 27(3):141-147.
16. Gimenez-Roqueplo A.P., Dahia P.L., Robledo M. An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Horm Metab Res 2012, 44(5):328-333.
17. Latif F., Tory K., Gnarra J., et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993, 260(5112):1317-1320.
18. Wallace M.R., Marchuk D.A., Andersen L.B., et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 1990, 249(4965):181-186.
19. Burnichon N., Buffet A., Parfait B., et al. Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Hum Mol Genet 2012, 21(26):5397-5405.
20. Baysal B.E., Ferrell R.E., Willett-Brozick J.E., et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000, 287(5454):848-851.
21. Astuti D., Latif F., Dallol A., et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 2001, 69(1):49-54.
22. Niemann S., Müller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 2000, 26(3):268-270.
23. Burnichon N., Briere J.J., Libé R., et al. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet 2010, 19(15):3011-3020.
24. Hao H.X., Khalimonchuk O., Schraders M., et al. SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science 2009, 325(5944):1139-1142.
25. Yang C., Matro J.C., Huntoon K.M., et al. Missense mutations in the human SDHB gene increase protein degradation without altering intrinsic enzymatic function. FASEB J 2012, 26(11):4506-4516.
26. Timmers H.J., Pacak K., Huynh T.T., et al. Biochemically silent abdominal paragangliomas in patients with mutations in the succinate dehydrogenase subunit B gene. J Clin Endocrinol Metab 2008, 93(12):4826-4832.
27. Timmers H.J., Gimenez-Roqueplo A.P., Mannelli M., Pacak K., et al. Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. Endocr Relat Cancer 2009, 16(2):391-400.
28. Ghayee H.K., Havekes B., Corssmit E.P.M., et al. Mediastinal paragangliomas: association with mutations in the succinate dehydrogenase genes and aggressive behavior. Endocr Relat Cancer 2009, 16(1):291-299.
29. Lodish M.B., Adams K.T., Huynh T.T., et al. Succinate dehydrogenase gene mutations are strongly associated with paraganglioma of the organ of Zuckerkandl. Endocr Relat Cancer 2010, 17(3):581-588.
30. Benn D.E., Gimenez-Roqueplo A.P., Reilly J.R., et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab 2006, 91(3):827-836.
31. van Duinen N., Corssmit E.P., de Jong W.H., Brookman D., Kema I.P., Romijn J.A. Plasma levels of free metanephrines and 3-methoxytyramine indicate a higher number of biochemically active HNPGL than 24-h urinary excretion rates of catecholamines and metabolites. Eur J Endocrinol 2013, 169(3):377-382.
32. Baysal B.E. Mitochondrial complex II and genomic imprinting in inheritance of paraganglioma tumors. Biochim Biophys Acta 2013, 1827(5):573-577.
33. van Hulsteijn L.T., Dekkers O.M., Hes F.J., Smit J.W., Corssmit E.P. Risk of malignant paraganglioma in SDHB-mutation and SDHD-mutation carriers: a systematic review and meta-analysis. J Med Genet 2012, 49(12):768-776.
34. Brouwers F.M., Eisenhofer G., Tao J.J., et al. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab 2006, 91(11):4505-4509.
35. Papathomas T.G., Gaal J., Corssmit E.P., et al. Non-pheochromocytoma/paraganglioma tumors in patients with succinate dehydrogenase-related pheochromocytoma-paraganglioma syndromes: a clinicopathologic and molecular analysis. Eur J Endocrinol 2013, 170(1):1-12.
36. Ricketts C., Woodward E.R., Killick P., et al. Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst 2008, 100(17):1260-1262.
37. Ricketts C.J., Forman J.R., Rattenberry E., et al. Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Hum Mutat 2010, 31(1):41-51.
38. Ayala-Ramirez M., Callender G.G., Kupferman M.E., et al. Paraganglioma syndrome type 1 in a patient with Carney-Stratakis syndrome. Nat Rev Endocrinol 2010, 6(2):110-115.
39. Pasini B., McWhinney S.R., Bei T., et al. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet 2008, 16(1):79-88.
40. Dwight T., Mann K., Benn D.E., et al. Familial SDHA mutation associated with pituitary adenoma and pheochromocytoma/paraganglioma. J Clin Endocrinol Metab 2013, 98(6):E1103-E1108.
41. Xekouki P., Stratakis C.A. Succinate dehydrogenase (SDHx) mutations in pituitary tumors: could this be a new role for mitochondrial complex II and/or Krebs cycle defects?. Endocr Relat Cancer 2012, 19(6):C33-C40.
42. Schimke R.N., Collins D.L., Stolle C.A. Paraganglioma neuroblastoma, and a SDHB mutation: resolution of a 30-year-old mystery. Am J Med Genet A 2010, 152A(6):1531-1535.
43. Armstrong R., Greenhalgh K.L., Rattenberry E., et al. Succinate dehydrogenase subunit B (SDHB) gene deletion associated with a composite paraganglioma/neuroblastoma. J Med Genet 2009, 46(3):215-216.
44. Cascón A., Landa I., López-Jiménez E., et al. Molecular characterisation of a common SDHB deletion in paraganglioma patients. J Med Genet 2008, 45(4):233-238.
45. Ni Y., Zbuk K.M., Sadler T., et al. Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes. Am J Hum Genet 2008, 83(2):261-268.
46. Kim S., Kim D.H., Jung W.H., Koo J.S. Succinate dehydrogenase expression in breast cancer. Springerplus 2013, 2(1):299.
47. Neumann H.P.H., Pawlu C., Peczkowska M., et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. J Am Med Assoc 2004, 292(8):943-951.
48. Schiavi F., Milne R.L., Anda E., et al. Are we overestimating the penetrance of mutations in SDHB?. Hum Mutat 2010, 31(6):761-762.
49. Gimenez-Roqueplo A.P., Favier J., Rustin P., et al. Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. J Clin Endocrinol Metab 2002, 87(10):4771-4774.
50. Rao J.U., Engelke U.F.H., Rodenburg R.J.T., et al. Genotype-specific abnormalities in mitochondrial function associate with distinct profiles of energy metabolism and catecholamine content in pheochromocytoma and paraganglioma. Clin Cancer Res 2013, 19(14):3787-3795.
51. Letouzé E., Martinelli C., Loriot C., et al. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell 2013, 23(6):739-752.
52. Castelblanco E., Santacana M., Valls J., et al. Usefulness of negative and weak-diffuse pattern of SDHB immunostaining in assessment of SDH mutations in paragangliomas and pheochromocytomas. Endocr Pathol 2013, 24(4):199-205.
53. Gill A.J., Benn D.E., Chou A., et al. Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes. Hum Pathol 2010, 41(6):805-814.
54. van Nederveen F.H., Gaal J., Favier J., et al. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol 2009, 10(8):764-771.
55. Korpershoek E., Favier J., Gaal J., et al. SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab 2011, 96(9):E1472-E1476.
56. Comino-Méndez I., Gracia-Aznárez F., Schiavi F., et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet 2011, 43(7):663-667.
57. Burnichon N., Cascón A., Schiavi F., et al. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res 2012, 18(10):2828-2837.
58. Peczkowska M., Kowalska A., Sygut J., et al. Testing new susceptibility genes in the cohort of apparently sporadic phaeochromocytoma/paraganglioma patients with clinical characteristics of hereditary syndromes. Clin Endocrinol (Oxf) 2013, 10.1111/cen.12218.
59. Qin Y., Yao L., King E.E., et al. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet 2010, 42(3):229-233.
60. Jiang S., Dahia P.L. Minireview: the busy road to pheochromocytomas and paragangliomas has a new member, TMEM127. Endocrinology 2011, 152(6):2133-2140.
61. Zhuang Z., Yang C., Lorenzo F., et al. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med 2012, 367(10):922-930.
62. Pacak K., Jochmanova I., Prodanov T., et al. New syndrome of paraganglioma and somatostatinoma associated with polycythemia. J Clin Oncol 2013, 31(13):1690-1698.
63. Toledo R.A., Qin Y., Srikantan S., et al. In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas. Endocr Relat Cancer 2013, 20(3):349-359.
64. Taïeb D., Yang C., Delenne B., et al. First report of bilateral pheochromocytoma in the clinical spectrum of HIF2A-related polycythemia-paraganglioma syndrome. J Clin Endocrinol Metab 2013, 98(5):E908-E913.
65. Yang C., Sun M.G., Matro J., et al. Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas. Blood 2013, 121(13):2563-2566.
66. Lorenzo F.R., Yang C., Ng Tang Fui M., et al. A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. J Mol Med (Berl) 2013, 91(4):507-512.
67. Comino-Méndez I., de Cubas A.A., Bernal C., et al. Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. Hum Mol Genet 2013, 22(11):2169-2176.
68. Gaal J., Burnichon N., Korpershoek E., et al. Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 2010, 95(3):1274-1278.
69. Schlisio S., Kenchappa R.S., Vredeveld L.C.W., et al. The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev 2008, 22(7):884-893.
70. Ladroue C., Carcenac R., Leporrier M., et al. PHD2 mutation and congenital erythrocytosis with paraganglioma. N Engl J Med 2008, 359(25):2685-2692.
71. Tomlinson I.P.M., Alam N.A., Rowan A.J., et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002, 30(4):406-410.
72. Wadt K., Cho J., Chung J.Y., et al. A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma. Pigment Cell Melanoma Res 2012, 25(6):815-818.
73. Crona J., Delgado Verdugo A., Maharjan R., et al. Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing. J Clin Endocrinol Metab 2013, 98(7):E1266-E1271.
74. Eisenhofer G., Lenders J.W., Timmers H., et al. Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem 2011, 57(3):411-420.
75. Rattenberry E., Vialard L., Yeung A., et al. A comprehensive next generation sequencing-based genetic testing strategy to improve diagnosis of inherited pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 2013, 98(7):E1248-E1256.
76. McInerney-Leo A.M., Marshall M.S., Gardiner B., et al. Whole exome sequencing is an efficient and sensitive method for detection of germline mutations in patients with phaeochromocytomas and paragangliomas. Clin Endocrinol (Oxf) 2014, 80(1):25-33.
77. Dahia P.L.M., Ross K.N., Wright M.E., et al. A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet 2005, 1(1):72-80.
78. Eisenhofer G., Huynh T.T., Pacak K., et al. Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocr Relat Cancer 2004, 11(4):897-911.
79. Favier J., Briere J.J., Burnichon N., et al. The Warburg effect is genetically determined in inherited pheochromocytomas. PloS One 2009, 4(9):e7094.
80. Favier J., Gimenez-Roqueplo A.P. Pheochromocytomas: the (pseudo)-hypoxia hypothesis. Best Pract Res Clin Endocrinol Metab 2010, 24(6):957-968.
81. López-Jiménez E., Gómez-López G., Leandro-García L.J., et al. Research resource: transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol Endocrinol 2010, 24(12):2382-2391.
82. Pollard P.J., El-Bahrawy M., Poulsom R., et al. Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations. J Clin Endocrinol Metab 2006, 91(11):4593-4598.
83. Shankavaram U., Fliedner S.M.J., Elkahloun A.G., et al. Genotype and tumor locus determine expression profile of pseudohypoxic pheochromocytomas and paragangliomas. Neoplasia 2013, 15(4):435-447.
84. de Cubas A.A., Leandro-García L.J., Schiavi F., et al. Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways. Endocr Relat Cancer 2013, 20(4):477-493.
85. Meyer-Rochow G.Y., Jackson N.E., Conaglen J.V., et al. MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets. Endocr Relat Cancer 2010, 17(3):835-846.
86. Patterson E., Webb R., Weisbrod A., et al. The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocytoma. Endocr Relat Cancer 2012, 19(2):157-166.
87. Tömböl Z., Eder K., Kovács A., et al. MicroRNA expression profiling in benign (sporadic and hereditary) and recurring adrenal pheochromocytomas. Mod Pathol 2010, 23(12):1583-1595.
88. Lee S., Nakamura E., Yang H., et al. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 2005, 8(2):155-167.
89. Saldana M.J., Salem L.E., Travezan R. High altitude hypoxia and chemodectomas. Hum Pathol 1973, 4(2):251-263.
90. Jochmanová I., Yang C., Zhuang Z., Pacak K. Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction. J Natl Cancer Inst 2013, 105(17):1270-1283.
91. Mazza A., Armigliato M., Marzola M.C., et al. Anti-hypertensive treatment in pheochromocytoma and paraganglioma: current management and therapeutic features. Endocrine 2013, 10.1007/s12020-013-0007-y.
92. King K.S., Darmani N.A., Hughes M.S., Adams K.T., Pacak K. Exercise-induced nausea and vomiting: another sign and symptom of pheochromocytoma and paraganglioma. Endocrine 2010, 37(3):403-407.
93. La Batide-Alanore A., Chatellier G., Plouin P.F. Diabetes as a marker of pheochromocytoma in hypertensive patients. J Hypertens 2003, 21(9):1703-1707.
94. Whitelaw B.C., Prague J.K., Mustafa O.G., et al. Pheochromocytoma crisis. Clin Endocrinol (Oxf) 2013, 80(1):13-22.
95. Lenders J.W.M., Pacak K., Walther M.M., et al. Biochemical diagnosis of pheochromocytoma: which test is best?. J Am Med Assoc 2002, 287(11):1427-1434.
96. Eisenhofer G., Goldstein D.S., Sullivan P., et al. Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. J Clin Endocrinol Metab 2005, 90(4):2068-2075.
97. Poirier É., Thauvette D., Hogue J.C. Management of exclusively dopamine-secreting abdominal pheochromocytomas. J Am Coll Surg 2013, 216(2):340-346.
98. Eisenhofer G., Lenders J.W., Siegert G., et al. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer 2012, 48(11):1739-1749.
99. Eiden L.E., Iacangelo A., Hsu C.M., Hotchkiss A.J., Bader M.F., Aunis D. Chromogranin A synthesis and secretion in chromaffin cells. J Neurochem 1987, 49(1):65-74.
100. Grossrubatscher E., Dalino P., Vignati F., et al. The role of chromogranin A in the management of patients with phaeochromocytoma. Clin Endocrinol (Oxf) 2006, 65(3):287-293.
101. d'Herbomez M., Do Cao C., Vezzosi D., et al. Chromogranin A assay in clinical practice. Ann Endocrinol 2010, 71(4):274-280.
102. Cleary S., Phillips J.K., Huynh T.T., et al. Chromogranin A expression in phaeochromocytomas associated with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. Horm Metab Res 2007, 39(12):876-883.
103. Eisenhofer G., Goldstein D.S., Walther M.M., et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab 2003, 88(6):2656-2666.
104. Eisenhofer G., Siegert G., Kotzerke J., Bornstein S.R., Pacak K. Current progress and future challenges in the biochemical diagnosis and treatment of pheochromocytomas and paragangliomas. Horm Metab Res 2008, 40(5):329-337.
105. Neary N.M., King K.S., Pacak K. Drugs and pheochromocytoma-don[U+05F3]t be fooled by every elevated metanephrine. N Engl J Med 2011, 364(23):2268-2270.
106. Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab 2007, 92(11):4069-4079.
107. Niculescu D.A., Ismail G., Poiana C. Plasma free metanephrine and normetanephrine levels are increased in patients with chronic kidney disease. Endocr Pract 2013, 10.4158/EP13251.OR.
108. Lenders J.W.M., Pacak K., Huynh T.T., et al. Low sensitivity of glucagon provocative testing for diagnosis of pheochromocytoma. J Clin Endocrinol Metab 2010, 95(1):238-245.
109. Nijhoff M.F., Dekkers O.M., Vleming L.J., Smit J.W., Romijn J.A., Pereira A.M. ACTH-producing pheochromocytoma: clinical considerations and concise review of the literature. Eur J Intern Med 2009, 20(7):682-685.
110. Kumar M., Kumar V., Talukdar B., Mohta A., Khurana N. Cushing syndrome in an infant due to cortisol secreting adrenal pheochromocytoma: a rare association. J Pediatr Endocrinol Metab 2010, 23(6):621-625.
111. Berenyi M.R., Singh G., Gloster E.S., Davidson M.I., Woldnenberg D.H. ACTH-producing pheochromocytoma. Arch Pathol Lab Med 1977, 101(1):31-35.
112. Därr R., Pamporaki C., Peitzsch M., et al. Biochemical diagnosis of phaeochromocytoma using plasma free normetanephrine, metanephrine and methoxytyramine: importance of supine sampling under fasting conditions. Clin Endocrinol (Oxf) 2013, 10.1111/cen.12327.
113. Eisenhofer G., Lattke P., Herberg M., et al. Reference intervals for plasma free metanephrines with an age adjustment for normetanephrine for optimized laboratory testing of phaeochromocytoma. Ann Clin Biochem 2013, 50(Pt1):62-69.
114. Taïeb D., Timmers H.J., Hindié E., et al. EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2012, 39(12):1977-1995.
115. 123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clin Endocrinol (Oxf) 2008, 69(2):181-188.
116. Havekes B., King K., Lai E.W., Romijn J.A., Corssmit E.P, Pacak K. New imaging approaches to phaeochromocytomas and paragangliomas. Clin Endocrinol (Oxf) 2010, 72(2):137-145.
117. Leung K., Stamm M., Raja A., Low G. Pheochromocytoma: the range of appearances on ultrasound, CT, MRI, and functional imaging. Am J Roentgenol 2013, 200(2):370-378.
118. Northcutt B.G., Raman S.P., Long C., et al. MDCT of adrenal masses: can dual-phase enhancement patterns be used to differentiate adenoma and pheochromocytoma?. Am J Roentgenol 2013, 201(4):834-839.
119. Chen C.C., Carrasquillo J.A. Molecular imaging of adrenal neoplasms. J Surg Oncol 2012, 106(5):532-542.
120. 131I]-metaiodobenzylguanidine scintigraphy. Int J Urol 1999, 6(3):119-124.
121. 123I-mIBG SPECT/CT, and MRI for the detection of adrenal pheochromocytoma in patients with elevated urine or plasma catecholamines. Clin Nucl Med 2013, 38(1):e1-e6.
122. 123I-mIBG SPECT/CT, and MRI for the detection of adrenal pheochromocytoma in patients with elevated urine or plasma catecholamines. Clin Nucl Med 2013, 38(10):810.
123. 124I]mIBG PET/MR. J Clin Endocrinol Metab 2012, 97(11):3833-3834.
124. Maurea S., Cuocolo A., Imbriaco M., et al. Imaging characterization of benign and malignant pheochromocytoma or paraganglioma: comparison between MIBG uptake and MR signal intensity ratio. Ann Nucl Med 2012, 26(8):670-675.
125. 123I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease. Endocr Relat Cancer 2012, 19(1):83-93.
126. Apeldoorn L., Voerman H.J., Hoefnagel C.A. Interference of MIBG uptake by medication: a case report. Neth J Med 1995, 46(5):239-243.
127. 18F-FDG PET/CT. Acta Radiol 2013, 10.1177/0284185113504330.
128. 18F-FDG) positron emission tomography. J Natl Cancer Inst 2012, 104(9):700-708.
129. Zelinka T., Timmers H.J., Kozupa A., et al. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations. Endocr Relat Cancer 2008, 15(1):311-323.
130. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas. J Nucl Med 2009, 50(4):513-519.
131. 18F-Fluoro-l-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. J Nucl Med 2007, 48(10):1599-1606.
132. 111In-pentetreotide scintigraphy. J Clin Endocrinol Metab 2011, 96(9):2779-2785.
133. 18F-DOPA PET/CT in the Evaluation of Hereditary SDH-Deficiency Paraganglioma-Pheochromocytoma Syndromes. Clin Nucl Med 2014, 39(1):e53-e58.
134. 18F]fluorodihydroxyphenylalanine PET. Eur J Nucl Med Mol Imaging 2013, 40(6):889-896.
135. Gabriel S., Blanchet E.M., Sebag F., et al. Functional characterization of nonmetastatic paraganglioma and pheochromocytoma by (18) F-FDOPA PET: focus on missed lesions. Clin Endocrinol (Oxf) 2013, 79(2):170-177.
136. 111In-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med 2008, 49(10):1613-1619.
137. 18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 2001, 38(1):6-8.
138. 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 2009, 94(12):4757-4767.
139. 18F]-fluorodopamine positron emission tomography (PET) as first-line investigation for the diagnosis and localization of non-metastatic and metastatic phaeochromocytoma (PHEO). Clin Endocrinol (Oxf) 2009, 71(1):11-17.
140. Blanchet E.M., Martucci V., Millo C., Chen C.C., Herscovitch P., Pacak K. Multitracer PET imaging of bone metastases from paraganglioma: peripheral halo of uptake on (18)F-FLT PET mismatching with central uptake of (18)F-FDOPA, (18)F-fluorodopamine, and (18)F-FDG. Eur J Nucl Med Mol Imaging 2013, 40(12):1928-1929.
141. 68Ga-DOTA-NOC PET. Biomed Pharmacother 2008, 62(10):667-671.
142. 123I-metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging 2011, 38(5):865-873.
143. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT. Eur J Nucl Med Mol Imaging 2013, 40(4):514-523.
144. Kroiss A., Putzer D., Frech A., et al. A retrospective comparison between (68)Ga-DOTA-TOC PET/CT and (18)F-DOPA PET/CT in patients with extra-adrenal paraganglioma. Eur J Nucl Med Mol Imaging 2013, 40(12):1800-1808.
145. 123I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2012, 39(8):1266-1270.
146. 123I-MIBG in identifying malignant neural crest tumours. Mol Imaging Biol 2011, 13(4):769-775.
147. 68Ga-DOTA-NOC PET-CT in phaeochromocytoma and paraganglioma: preliminary results from a single centre study. Eur Radiol 2012, 22(3):710-719.
148. Naswa N., Sharma P., Soundararajan R., et al. Preoperative characterization of indeterminate large adrenal masses with dual tracer PET-CT using fluorine-18 fluorodeoxyglucose and gallium-68-DOTANOC: initial results. Diagn Interv Radiol 2013, 19(4):294-298.
149. 68Ga-DOTANOC PET/CT for baseline evaluation of patients with head and neck paraganglioma. J Nucl Med 2013, 54(6):841-847.
150. 68Ga-DOTATATE PET in neuroectodermal tumours: first experience. Nucl Med Commun 2007, 28(5):359-363.
151. Mundschenk J., Unger N., Schulz S., et al. Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab 2003, 88(11):5150-5157.
152. Gimenez-Roqueplo A.P., Caumont-Prim A., Houzard C., et al. Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA Investigators. J Clin Endocrinol Metab 2013, 98(1):E162-E173.
153. Jasperson K.W., Kohlmann W., Gammon A., et al. Role of rapid sequence whole-body MRI screening in SDH-associated hereditary paraganglioma families. Fam Cancer 2013, 10.1007/s10689-013-9639-6.
154. Thompson L.D. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 2002, 26(5):551-566.
155. Agarwal A., Mehrotra P.K., Jain M., et al. Size of the tumor and pheochromocytoma of the adrenal gland scaled score (PASS): can they predict malignancy?. World J Surg 2010, 34(12):3022-3028.
156. de Wailly P., Oragano L., Radé F., et al. Malignant pheochromocytoma: new malignancy criteria. Langenbecks Arch Surg 2012, 397(2):239-246.
157. Tavangar S.M., Shojaee A., Moradi Tabriz H., et al. Immunohistochemical expression of Ki67, c-erbB-2, and c-kit antigens in benign and malignant pheochromocytoma. Pathol Res Pract 2010, 206(5):305-309.
158. Lin M., Wong V., Yap J., Jin R., Leong P., Campbell P. FDG PET in the evaluation of phaeochromocytoma: a correlative study with MIBG scintigraphy and Ki-67 proliferative index. Clin Imaging 2013, 37(6):1084-1088.
159. Brouwers F.M., Elkahloun A.G., Munson P.J., et al. Gene expression profiling of benign and malignant pheochromocytoma. Ann N Y Acad Sci 2006, 1073:541-556.
160. Xu Y., Qi Y., Rui W., et al. Expression and diagnostic relevance of heat shock protein 90 and signal transducer and activator of transcription 3 in malignant pheochromocytoma. J Clin Pathol 2013, 66(4):286-290.
161. Boltze C., Mundschenk J., Unger N., et al. Expression profile of the telomeric complex discriminates between benign and malignant pheochromocytoma. J Clin Endocrinol Metab 2003, 88(9):4280-4286.
162. Favier J., Plouin P.F., Corvol P., Gasc J.M. Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors. Am J Pathol 2002, 161(4):1235-1246.
163. Salmenkivi K., Heikkilä P., Liu J., Haglund C., Arola J. VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome. Acta Pathol Microbiol Immunol Scand 2003, 111(4):458-464.
164. Lee T.K., Murthy S.R.K., Cawley N.X., et al. An N-terminal truncated carboxypeptidase E splice isoform induces tumor growth and is a biomarker for predicting future metastasis in human cancers. J Clin Invest 2011, 121(3):880-892.
165. Amar L., Baudin E., Burnichon N., et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab 2007, 92(10):3822-3828.
166. Plouin P.F., Fitzgerald P., Rich T., et al. Metastatic pheochromocytoma and paraganglioma: focus on therapeutics. Horm Metab Res 2012, 44(5):390-399.
167. Ayala-Ramirez M., Feng L., Johnson M.M., et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab 2011, 96(3):717-725.
168. Park J., Song C., Park M., et al. Predictive characteristics of malignant pheochromocytoma. Korean J Urol 2011, 52(4):241-246.
169. Zelinka T., Musil Z., Duskova J., et al. Metastatic pheochromocytoma: does the size and age matter?. Eur J Clin Invest 2011, 41(10):1121-1128.
170. Goffredo P., Sosa J.A., Roman S.A. Malignant pheochromocytoma and paraganglioma: a population level analysis of long-term survival over two decades. J Surg Oncol 2013, 107(6):659-664.
171. Jimenez C., Rohren E., Habra M.A., et al. Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma. Curr Oncol Rep 2013, 15(4):356-371.
172. van Hulsteijn L.T., Louisse A., Havekes B., et al. Quality of life is decreased in patients with paragangliomas. Eur J Endocrinol 2013, 168(5):689-697.
173. Ayala-Ramirez M., Palmer J.L., Hofmann M.C., et al. Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma. J Clin Endocrinol Metab 2013, 98(4):1492-1497.
174. Adjallé R., Plouin P.F., Pacak K., Lehnert H. Treatment of malignant pheochromocytoma. Horm Metab Res 2009, 41(9):687-696.
175. Hescot S., Leboulleux S., Amar L., et al. One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 2013, 98(10):4006-4012.
176. Conzo G., Musella M., Corcione F., et al. Laparoscopic adrenalectomy, a safe procedure for pheochromocytoma. A retrospective review of clinical series. Int J Surg 2013, 11(2):152-156.
177. Goldstein R.E., O'Neill J.A., Holcomb G.W., et al. Clinical experience over 48 years with pheochromocytoma. Ann Surg 1999, 229(6):755-764. [discussion 764-766].
178. Cheah W.K., Clark O.H., Horn J.K., Siperstein A.E., Duh Q.Y. Laparoscopic adrenalectomy for pheochromocytoma. World J Surg 2002, 26(8):1048-1051.
179. Goers T.A., Abdo M., Moley J.F., Matthews B.D., Quasebarth M., Brunt L.M. Outcomes of resection of extra-adrenal pheochromocytomas/paragangliomas in the laparoscopic era: a comparison with adrenal pheochromocytoma. Surg Endosc 2013, 27(2):428-433.
180. Henry J.F., Defechereux T., Raffaelli M., Lubrano D., Gramatica L. Complications of laparoscopic adrenalectomy: results of 169 consecutive procedures. World J Surg 2000, 24(11):1342-1346.
181. Hwang J.J., Shoaf G., Uchio E.M., et al. Laparoscopic management of extra-adrenal pheochromocytoma. J Urol 2004, 171(1):72-76.
182. Janetschek G., Finkenstedt G., Gasser R., et al. Laparascopic surgery for pheochromocytoma: adrenalectomy, partial resection, excision of paragangliomas. J Urol 1998, 160(2):330-334.
183. Sprung J., O'Hara J.F., Gill I.S., Abdelmalak B., Sarnaik A., Bravo E.L. Anesthetic aspects of laparoscopic and open adrenalectomy for pheochromocytoma. Urology 2000, 55(3):339-343.
184. Vargas H.I., Kavoussi L.R., Bartlett D.L., et al. Laparoscopic adrenalectomy: a new standard of care. Urology 1997, 49(5):673-678.
185. Walz M.K., Peitgen K., Neumann H.P.H., Janssen O.E., Philipp T., Mann K. Endoscopic treatment of solitary, bilateral, multiple, and recurrent pheochromocytomas and paragangliomas. World J Surg 2002, 26(8):1005-1012.
186. Aliyev S., Karabulut K., Agcaoglu O., et al. Robotic versus laparoscopic adrenalectomy for pheochromocytoma. Ann Surg Oncol 2013, 20(13):4190-4194.
187. Brauckhoff M., Gimm O., Brauckhoff K., Dralle H. Repeat adrenocortical-sparing adrenalectomy for recurrent hereditary pheochromocytoma. Surg Today 2004, 34(3):251-255.
188. Fallon S.C., Feig D., Lopez M.E., Brandt M.L. The utility of cortical-sparing adrenalectomy in pheochromocytomas associated with genetic syndromes. J Pediatr Surg 2013, 48(6):1422-1425.
189. Grubbs E.G., Rich T.A., Ng C., et al. Long-term outcomes of surgical treatment for hereditary pheochromocytoma. J Am Coll Surg 2013, 216(2):280-289.
190. Neumann H.P.H., Reincke M., Bender B.U., Elsner R., Janetschek G. Preserved adrenocortical function after laparoscopic bilateral adrenal sparing surgery for hereditary pheochromocytoma. J Clin Endocrinol Metab 1999, 84(8):2608-2610.
191. Volkin D., Yerram N., Ahmed F., et al. Partial adrenalectomy minimizes the need for long-term hormone replacement in pediatric patients with pheochromocytoma and von Hippel-Lindau syndrome. J Pediatr Surg 2012, 47(11):2077-2082.
192. Walther M.M., Herring J., Choyke P.L., Linehan W.M. Laparascopic partial adrenalectomy in patients with hereditary forms of pheochromocytoma. J Urol 2000, 164(1):14-17.
193. Yip L., Lee J.E., Shapiro S.E., et al. Surgical management of hereditary pheochromocytoma. J Am Coll Surg 2004, 198(4):525-534.
194. Plouin P.F., Chatellier G., Fofol I., Corvol P. Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension 1997, 29(5):1133-1139.
195. Ellis R.J., Patel D., Prodanov T., et al. Response after surgical resection of metastatic pheochromocytoma and paraganglioma: can postoperative biochemical remission be predicted?. J Am Coll Surg 2013, 217(3):489-496.
196. Mamlouk M.D., van Sonnenberg E., Stringfellow G., Smith D., Wendt A. Radiofrequency ablation and biopsy of metastatic pheochromocytoma: emphasizing safety issues and dangers. J Vasc Interv Radiol 2009, 20(5):670-673.
197. McBride J.F., Atwell T.D., Charboneau W.J., Young W.F., Wass T.C., Callstrom M.R. Minimally invasive treatment of metastatic pheochromocytoma and paraganglioma: efficacy and safety of radiofrequency ablation and cryoablation therapy. J Vasc Interv Radiol 2011, 22(9):1263-1270.
198. Pacak K., Fojo T., Goldstein D.S., et al. Radiofrequency ablation: a novel approach for treatment of metastatic pheochromocytoma. J Natl Cancer Inst 2001, 93(8):648-649.
199. Venkatesan A.M., Locklin J., Lai E.W., et al. Radiofrequency ablation of metastatic pheochromocytoma. J Vasc Interv Radiol 2009, 20(11):1483-1490.
200. 131I-MIBG. Horm Metab Res 2012, 44(5):405-410.
201. Chino J.P., Sampson J.H., Tucci D.L., Brizel D.M., Kirkpatrick J.P. Paraganglioma of the head and neck: long-term local control with radiotherapy. Am J Clin Oncol 2009, 32(3):304-307.
202. Li G., Chang S., Adler J.R., Lim M. Irradiation of glomus jugulare tumors: a historical perspective. Neurosurg Focus 2007, 23(6):E13.
203. Lim M., Bower R., Nangiana J.S., Adler J.R., Chang S.D. Radiosurgery for glomus jugulare tumors. Technol Cancer Res Treat 2007, 6(5):419-423.
204. Poznanovic S.A., Cass S.P., Kavanagh B.D. Short-term tumor control and acute toxicity after stereotactic radiosurgery for glomus jugulare tumors. Otolaryngol Head Neck Surg 2006, 134(3):437-442.
205. Wegner R.E., Rodriguez K.D., Heron D.E., Hirsch B.E., Ferris R.L., Burton S.A. Linac-based stereotactic body radiation therapy for treatment of glomus jugulare tumors. Radiother Oncol 2010, 97(3):395-398.
206. Carrasquillo J.A., Pandit-Taskar N., Chen C.C. Radionuclide therapy of adrenal tumors. J Surg Oncol 2012, 106(5):632-642.
207. 131I-mIBG) therapy. Eur J Nucl Med Mol Imaging 2008, 35(5):1039-1047.
208. 131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest 1997, 20(11):648-658.
209. 131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol 2009, 27(25):4162-4168.
210. van Hulsteijn L.T., Niemeijer N.D., Dekkers O.M., Corssmit E.P. (131)I-MIBG therapy for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf) 2013, 10.1111/cen.12341.
211. 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors. J Nucl Med 2010, 51(10):1524-1531.
212. 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL). Horm Metab Res 2012, 44(5):411-414.
213. 177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med 2006, 47(10):1599-1606.
214. Forrer F., Riedweg I., Maecke H.R., Mueller-Brand J. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging 2008, 52(4):334-340.
215. Averbuch S.D., Steakley C.S., Young R.C., et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 2008, 109(4):267-273.
216. Ayala-Ramirez M., Feng L., Habra M.A., et al. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience. Cancer 2012, 118(11):2804-2812.
217. Tanabe A., Naruse M., Nomura K., Tsuiki M., Tsumagari A., Ichihara A. Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma. Horm Cancer 2013, 4(2):103-110.
218. Huang H., Abraham J., Hung E., et al. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer 2008, 113(8):2020-2028.
219. Feldman J.M. Treatment of metastatic pheochromocytoma with streptozocin. Arch Intern Med 1983, 143(9):1799-1800.
220. Srimuninnimit V., Wampler G.L. Case report of metastatic familial pheochromocytoma treated with cisplatin and 5-fluorouracil. Cancer Chemother Pharmacol 1991, 28(3):217-219.
221. Ekeblad S., Sundin A., Janson E.T., et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007, 13(10):2986-2991.
222. Kulke M.H., Stuart K., Enzinger P.C., et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006, 24(3):401-406.
223. Saito Y., Tanaka Y., Aita Y., et al. Sunitinib induces apoptosis in pheochromocytoma tumor cells by inhibiting VEGFR2/Akt/mTOR/S6K1 pathways through modulation of Bcl-2 and BAD. Am J Physiol Endocrinol Metab 2012, 302(6):E615-E625.
224. Aita Y., Ishii K., Saito Y., et al. Sunitinib inhibits catecholamine synthesis and secretion in pheochromocytoma tumor cells by blocking VEGF receptor 2 via PLC-γ-related pathways. Am J Physiol Endocrinol Metab 2012, 303(8):E1006-E1014.
225. Ayala-Ramirez M., Chougnet C.N., Habra M.A., et al. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab 2012, 97(11):4040-4050.
226. Jimenez C., Cabanillas M.E., Santarpia L., et al. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab 2009, 94(2):386-391.
227. Joshua A.M., Ezzat S., Asa S.L., et al. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. J Clin Endocrinol Metab 2009, 94(1):5-9.
228. Prochilo T., Savelli G., Bertocchi P., et al. Targeting VEGF-VEGFR pathway by sunitinib in peripheral primitive neuroectodermal tumor, paraganglioma and epithelioid hemangioendothelioma: three case reports. Case Rep Oncol 2013, 6(1):90-97.
229. Druce M.R., Kaltsas G.A., Fraenkel M., Gross D.J., Grossman A.B. Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001). Horm Metab Res 2009, 41(9):697-702.
230. Oh D.Y., Kim T.W., Park Y.S., et al. Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas. Cancer 2012, 118(24):6162-6170.
231. Matro J., Giubellino A., Pacak K. Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors. Horm Metab Res 2013, 45(2):147-153.
232. Giubellino A., Bullova P., Nolting S., et al. Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice. Endocrinology 2013, 154(2):646-655.
233. Jhaveri K., Taldone T., Modi S., Chiosis G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta 2012, 1823(3):742-755.
234. Giubellino A., Sourbier C., Lee M.J., et al. Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma. PloS One 2013, 8(2):e56083.
235. Zhang C., Xu Y., Chen D., et al. Effect of HSP90 inhibitor in pheochromocytoma PC12 cells: an experimental investigation. Tumour Biol 2013, 34(6):4065-4071.
236. Fernández M.C., Venara M., Nowicki S., Chemes H.E., Barontini M., Pennisi P.A. Igf-I regulates pheochromocytoma cell proliferation and survival in vitro and in vivo. Endocrinology 2012, 153(8):3724-3734.
237. Nölting S., Garcia E., Alusi G., et al. Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines. J Mol Endocrinol 2012, 49(2):79-96.
238. Lai E.W., Rodriguez O.C., Aventian M., et al. ErbB-2 induces bilateral adrenal pheochromocytoma formation in mice. Cell Cycle 2007, 6(15):1946-1950.
239. Yuan W., Wang W., Cui B., et al. Overexpression of ERBB-2 was more frequently detected in malignant than benign pheochromocytomas by multiplex ligation-dependent probe amplification and immunohistochemistry. Endocr Relat Cancer 2008, 15(1):343-350.
240. Li M., Kong Z.M., Liu Z.L. Antioxidant enzyme activities and lipid peroxidation induced by eicosapentaenoic acid (EPA) in PC12 cells. Cell Biol Toxicol 2006, 22(5):331-337.
241. 3H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors. Endocr Relat Cancer 2011, 18(1):143-157.
242. Pacak K., Sirova M., Giubellino A., et al. NF-κB inhibition significantly upregulates the norepinephrine transporter system, causes apoptosis in pheochromocytoma cell lines and prevents metastasis in an animal model. Int J Cancer 2012, 131(10):2445-2455.
243. Sordet O., Goldman A., Redon C., Solier S., Rao V.A., Pommier Y. Topoisomerase I requirement for death receptor-induced apoptotic nuclear fission. J Biol Chem 2008, 283(34):23200-23208.
244. Ogi C., Aruga A. Immunological monitoring of anticancer vaccines in clinical trials. Oncoimmunology 2013, 2(8):e26012.
245. Papewalis C., Kouatchoua C., Ehlers M., et al. Chromogranin A as potential target for immunotherapy of malignant pheochromocytoma. Mol Cell Endocrinol 2011, 335(1):69-77.
246. 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model. J Nucl Med 2006, 47(4):660-667.